Strategic Initiative

Slingshot members are tracking this corporate initiative:

Bristol-Myers Squibb (BMY) Signs Exclusive Worldwide License Agreement with Nitto Denko (NDEKY) for siRNA Therapy in Advanced Non-Alcoholic Steatohepatitis (NASH) and Cirrhosis

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Slingshot Insights Explained
Strategic Initiative Date
Announcement Date:
Nov 10, 2016
Projected Implementation:
Q4, 2016
Relevance Tracked Until:
Q4, 2018
Related Projects Image
  • Don’t see a project related to the strategic initiative you care about?

Related Keywords Global Commercialization Rights, Development Rights, Liver Fibrosis Candidates, Exclusive Worldwide License Agreement, Sirna Therapy, Advanced Non-alcoholic Steatohepatitis, Nash, Cirrhosis